Online citations, reference lists, and bibliographies.
← Back to Search

Cytoreductive Surgery And Hyperthermic Intrapleural Chemotherapy For Malignant Pleural Diseases: Preliminary Experience.

M. Migliore, D. Calvo, Alessandra Criscione, C. Viola, G. Privitera, C. Spatola, H. Parrà, S. Palmucci, N. Ciancio, R. Caltabiano, G. Di Maria
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Cytoreductive surgery and hyperthermic-intraoperative-intrapleural-chemotherapy (HITHOC) is a known approach for malignant pleural diseases (MPD). This study was started to clarify the role of cytoreductive surgery and HITHOC in MPD. Criteria of inclusion were early-stage disease in malignant pleural mesothelioma (MPM), young age, good condition and selected stage-M1a lung cancer. Six patients with MPM and two patients with lung cancer were enrolled. After surgical debulking, intrapleural cisplatin was administered for 60 min at 42.5°C. Wedge, rib resection and repaired diaphragm were added in three, one and one patient, respectively. Morbidity, toxicity and mortality was nil. Hospital stay was 8 days. Mean survival is 13.6 months. This experience confirms that cytoreductive surgery and HITHOC is a good option in the treatment of MPD. A randomized controlled trial is necessary.
This paper references
10.1016/j.lungcan.2011.12.009
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
O. Rena (2012)
10.1016/J.ATHORACSUR.2004.05.025
Intrapleural hyperthermic perfusion with chemotherapy increases apoptosis in malignant pleuritis.
Y. Matsuzaki (2004)
10.1183/2312508X.10012713
Lung cancer and pleural mesothelioma
G. D. Maria (2014)
Malignant pleural mesothelioma: factors influencing the prognosis.
T. Mineo (2012)
10.1093/ejcts/ezu217
Assessment of cisplatin concentration and depth of penetration in human lung tissue after hyperthermic exposure.
M. Ried (2015)
10.1200/JCO.2005.04.6813
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1093/ejcts/ezs418
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.
M. Ried (2013)
10.1016/S0140-6736(14)60418-9
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial
R. Rintoul (2014)
10.3238/arztebl.2013.0311
Progress means change: reflections on two articles about pleural disease.
T. Welte (2013)
10.1245/ASO.2003.03.022
Cytoreductive Surgery Combined With Intraoperative Hyperthermic Intrathoracic Chemotherapy for Stage I Malignant Pleural Mesothelioma
S. van Ruth (2003)
10.1136/thoraxjnl-2013-203846
Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position
A. Datta (2013)
10.1016/S0022-5223(03)00592-0
Efficacy and safety of single-trocar technique for minimally invasive surgery of the chest in the treatment of noncomplex pleural disease.
M. Migliore (2003)
10.12691/JCRT-2-1-1
Effect of Cytoreductive Surgery Combined with Intraoperative Intra-Thoracic Hyperthermic Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Myat Aung Kyaw (2014)
10.1016/j.jtcvs.2012.12.037
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
D. Sugarbaker (2013)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/j.rmed.2013.01.010
Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies.
A. Işık (2013)
10.3109/02656736.2013.829247
Cytoreductive surgery and post-operative heated pleural chemotherapy for the management of pleural surface malignancy
K. Kodama (2013)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1016/j.jtcvs.2014.03.011
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.
B. Burt (2014)
10.1016/j.athoracsur.2014.01.050
Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study.
L. Spaggiari (2014)
10.1016/j.jtcvs.2009.02.046
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
10.1186/1749-8090-10-S1-A9
Excision of the primary in stage IV non-small cell lung cancer (NSCLC): A feasibility study
A. Dawson (2015)
10.1016/j.jtcvs.2012.10.042
Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.
R. Cameron (2013)
10.11648/J.JCTR.20140201.11
Limitation of Pencil Beam Convolution (PBC) Algorithm for Photon Dose Calculations in Inhomogeneous Medium
Tesering Dorje (2014)
10.1016/S1547-4127(04)00108-2
External beam radiation therapy for the treatment of pleural mesothelioma.
E. Baldini (2004)
10.1016/S0140-6736(14)60795-9
Surgical resection of mesothelioma: an evidence-free practice
Y. Lee (2014)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1016/S0169-5002(14)70211-9
211 Excision of the primary in stage IV non-small cell lung cancer (NSCLC): A feasibility study
A. Dawson (2014)
10.1016/S0003-4975(00)01302-3
Thoracoscopic surgery, video-thoracoscopic surgery, or VATS: a confusion in definition.
M. Migliore (2000)
10.1378/CHEST.121.2.480
Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma.
E. de Bree (2002)
10.3238/arztebl.2013.0313
The treatment of pleural carcinosis with malignant pleural effusion.
M. Ried (2013)



This paper is referenced by
10.2217/FON-2016-0330
Intensity-modulated radiotherapy for relapsed malignant pleural mesothelioma.
C. Spatola (2016)
10.1007/s00398-018-0260-8
Intraoperative hypertherme intrathorakale Chemotherapie
T. Markowiak (2018)
10.21037/amj.2020.02.07
Non-small cell lung cancer, pleural effusion and carcinomatosis: always a criterion of inoperability?
P. Yablonskii (2020)
10.2217/fon-2018-0212
Surgery for "advanced" lung and esophageal cancer: new horizons or false dawn?
M. Migliore (2018)
10.1183/16000617.0018-2019
Does cytoreduction surgery and hyperthermic intrathoracic chemotherapy prolong survival in patients with N0–N1 nonsmall cell lung cancer and malignant pleural effusion?
M. Migliore (2019)
10.1007/s00104-019-0989-y
Hypertherme intrathorakale Chemotherapie in der Thoraxchirurgie
H. Hofmann (2019)
10.2217/fon.15.286
Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience.
M. Migliore (2015)
10.21147/j.issn.1000-9604.2017.06.07
Debulking surgery and hyperthermic intrathoracic chemotherapy (HITHOC) for lung cancer.
M. Migliore (2017)
10.21037/jtd.2016.06.04
Clinical outcomes of cytoreductive surgery combined with intrapleural perfusion of hyperthermic chemotherapy in advanced lung adenocarcinoma with pleural dissemination.
Eunjue Yi (2016)
10.1136/bmjopen-2020-041511
Protocol of a retrospective, multicentre observational study on hyperthermic intrathoracic chemotherapy in Germany
T. Markowiak (2020)
10.21037/shc.2018.06.06
Induction or adjuvant chemotherapy for radical multimodality therapy
Annabel J Sharkey (2018)
10.2217/fon.15.312
Management of recurrence after initial surgery for malignant pleural mesothelioma: a mini-review.
S. Halezeroğlu (2015)
Hyperthermic intraperitoneal chemotherapy is an independent risk factor for development of acute kidney injury
T. Dağel (2018)
10.35376/10324/16329
EFECTOS SOBRE LAS CÉLULAS PLEURALES MALIGNAS DE LA HIPERTERMIA Y CISPLATINO: SÍNTESIS DE PROTEÍNAS PRO-INFLAMATORIAS Y APOPTOSIS CELULAR
Gregorio Guitián Crespo (2016)
10.21037/AMJ-2019-MPE-07
Pleural carcinosis caused by extrathoracic malignancies
M. Migliore (2020)
10.1055/A-0934-7806
Expertenempfehlung zur Anwendung der hyperthermen intrathorakalen Chemotherapie (HITOC) in Deutschland
Michael Ried (2020)
10.21037/jtd.2017.04.65
Intrapleural perfusion thermo-chemotherapy for pleural effusion caused by lung carcinoma under VATS.
R. Hu (2017)
10.21037/tlcr.2018.06.07
Extended pleurectomy decortication: the current role.
R. Bilancia (2018)
10.18632/oncotarget.22062
Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis
Z. Zhao (2017)
10.4103/2395-3977.163804
Palliative Treatment of Malignant Pleural Effusion
C. Liu (2015)
Hyperthermic intrathoracic chemotherapy (HITHOC) in ovarian carcinoma - a propos of a case.
D. Stojiljković (2018)
10.1016/j.lungcan.2016.07.023
How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
A. Sharkey (2016)
10.1080/02656736.2017.1340676
Therapeutical effect of intrapleural perfusion with hyperthermic chemotherapy on malignant pleural effusion under video-assisted thoracoscopic surgery
X. Feng (2018)
10.21037/ATM.2020.03.58
Malignant pleural mesothelioma: between pragmatism and hope.
M. Migliore (2020)
10.2217/fon-2020-0279
Making precision surgical strategies a reality: are we ready for a paradigm shift in thoracic surgical oncology?
M. Migliore (2020)
10.1097/MD.0000000000005532
Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion
H. Zhou (2017)
Semantic Scholar Logo Some data provided by SemanticScholar